Cargando…

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy

PURPOSE: To compare the efficacies of photodynamic therapy (PDT) combined with intravitreal aflibercept (IVA) injections and IVA monotherapy using a treat-and-extend regimen (TAE) for treatment-naïve polypoidal choroidal vasculopathy (PCV). PATIENTS AND METHODS: One hundred and nine eyes treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyakubo, Tomoko, Mukai, Ryo, Matsumoto, Hidetaka, Morimoto, Masahiro, Takahashi, Maki, Nagai, Kazuki, Nakamura, Kosuke, Hoshino, Junki, Akiyama, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930588/
https://www.ncbi.nlm.nih.gov/pubmed/36817637
http://dx.doi.org/10.2147/OPTH.S386222
_version_ 1784889071373385728
author Miyakubo, Tomoko
Mukai, Ryo
Matsumoto, Hidetaka
Morimoto, Masahiro
Takahashi, Maki
Nagai, Kazuki
Nakamura, Kosuke
Hoshino, Junki
Akiyama, Hideo
author_facet Miyakubo, Tomoko
Mukai, Ryo
Matsumoto, Hidetaka
Morimoto, Masahiro
Takahashi, Maki
Nagai, Kazuki
Nakamura, Kosuke
Hoshino, Junki
Akiyama, Hideo
author_sort Miyakubo, Tomoko
collection PubMed
description PURPOSE: To compare the efficacies of photodynamic therapy (PDT) combined with intravitreal aflibercept (IVA) injections and IVA monotherapy using a treat-and-extend regimen (TAE) for treatment-naïve polypoidal choroidal vasculopathy (PCV). PATIENTS AND METHODS: One hundred and nine eyes treated with PDT combined with IVA (PDT+IVA group: 51 eyes) or IVA monotherapy (IVA group: 58 eyes) were assessed for 2 years. The main outcome measures included best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), number of IVA injections, and macular atrophy (MA). Polypoidal lesions before and after the loading phase were assessed using indocyanine green angiography. RESULTS: In both groups, BCVA significantly improved after the loading phase and was maintained for 2 years. CMT and CCT were significantly reduced in both groups, without significant differences after 2 years between the groups (P=0.2708). The mean number of IVA injections in the IVA and PDT+IVA groups during the 2 years were 13.2±3.3 and 12.7±1.8, respectively, without a significant difference (P=0.06). The frequencies of MA expansion in the IVA and PDT+IVA groups during the 2 years were 25.9% and 33.4%, respectively, with no significant difference in the incidence (odds ratio: 1.40, P=0.4253). The ratios of polyp regression after the loading phase in the IVA and PDT+IVA groups were 55.2% and 94.1%, respectively, with a significant difference (P<0.0001). CONCLUSION: PDT combined with IVA injections using a TAE regimen is effective for anatomical and visual function improvement, without a significant difference as compared to IVA monotherapy. It can facilitate complete regression of polyps with higher odds.
format Online
Article
Text
id pubmed-9930588
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-99305882023-02-16 Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Miyakubo, Tomoko Mukai, Ryo Matsumoto, Hidetaka Morimoto, Masahiro Takahashi, Maki Nagai, Kazuki Nakamura, Kosuke Hoshino, Junki Akiyama, Hideo Clin Ophthalmol Original Research PURPOSE: To compare the efficacies of photodynamic therapy (PDT) combined with intravitreal aflibercept (IVA) injections and IVA monotherapy using a treat-and-extend regimen (TAE) for treatment-naïve polypoidal choroidal vasculopathy (PCV). PATIENTS AND METHODS: One hundred and nine eyes treated with PDT combined with IVA (PDT+IVA group: 51 eyes) or IVA monotherapy (IVA group: 58 eyes) were assessed for 2 years. The main outcome measures included best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), number of IVA injections, and macular atrophy (MA). Polypoidal lesions before and after the loading phase were assessed using indocyanine green angiography. RESULTS: In both groups, BCVA significantly improved after the loading phase and was maintained for 2 years. CMT and CCT were significantly reduced in both groups, without significant differences after 2 years between the groups (P=0.2708). The mean number of IVA injections in the IVA and PDT+IVA groups during the 2 years were 13.2±3.3 and 12.7±1.8, respectively, without a significant difference (P=0.06). The frequencies of MA expansion in the IVA and PDT+IVA groups during the 2 years were 25.9% and 33.4%, respectively, with no significant difference in the incidence (odds ratio: 1.40, P=0.4253). The ratios of polyp regression after the loading phase in the IVA and PDT+IVA groups were 55.2% and 94.1%, respectively, with a significant difference (P<0.0001). CONCLUSION: PDT combined with IVA injections using a TAE regimen is effective for anatomical and visual function improvement, without a significant difference as compared to IVA monotherapy. It can facilitate complete regression of polyps with higher odds. Dove 2023-02-11 /pmc/articles/PMC9930588/ /pubmed/36817637 http://dx.doi.org/10.2147/OPTH.S386222 Text en © 2023 Miyakubo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Miyakubo, Tomoko
Mukai, Ryo
Matsumoto, Hidetaka
Morimoto, Masahiro
Takahashi, Maki
Nagai, Kazuki
Nakamura, Kosuke
Hoshino, Junki
Akiyama, Hideo
Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
title Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
title_full Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
title_fullStr Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
title_full_unstemmed Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
title_short Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
title_sort comparison of the 2-year results of photodynamic therapy with aflibercept and aflibercept monotherapy for polypoidal choroidal vasculopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930588/
https://www.ncbi.nlm.nih.gov/pubmed/36817637
http://dx.doi.org/10.2147/OPTH.S386222
work_keys_str_mv AT miyakubotomoko comparisonofthe2yearresultsofphotodynamictherapywithafliberceptandafliberceptmonotherapyforpolypoidalchoroidalvasculopathy
AT mukairyo comparisonofthe2yearresultsofphotodynamictherapywithafliberceptandafliberceptmonotherapyforpolypoidalchoroidalvasculopathy
AT matsumotohidetaka comparisonofthe2yearresultsofphotodynamictherapywithafliberceptandafliberceptmonotherapyforpolypoidalchoroidalvasculopathy
AT morimotomasahiro comparisonofthe2yearresultsofphotodynamictherapywithafliberceptandafliberceptmonotherapyforpolypoidalchoroidalvasculopathy
AT takahashimaki comparisonofthe2yearresultsofphotodynamictherapywithafliberceptandafliberceptmonotherapyforpolypoidalchoroidalvasculopathy
AT nagaikazuki comparisonofthe2yearresultsofphotodynamictherapywithafliberceptandafliberceptmonotherapyforpolypoidalchoroidalvasculopathy
AT nakamurakosuke comparisonofthe2yearresultsofphotodynamictherapywithafliberceptandafliberceptmonotherapyforpolypoidalchoroidalvasculopathy
AT hoshinojunki comparisonofthe2yearresultsofphotodynamictherapywithafliberceptandafliberceptmonotherapyforpolypoidalchoroidalvasculopathy
AT akiyamahideo comparisonofthe2yearresultsofphotodynamictherapywithafliberceptandafliberceptmonotherapyforpolypoidalchoroidalvasculopathy